The Use of Human Deoxyribonuclease (rhDNase) in the Management of Cystic Fibrosis

In patients with cystic fibrosis (CF), the poor clearance of airway secretions promotes recurrent cycles of pulmonary infection and inflammation. In recent years, novel drugs have been developed to alter the properties of the secretions in an attempt to aid chest physiotherapy in improving airway clearance. Once-daily nebulised recombinant human deoxyribonuclease (rhDNase; dornase alfa; Pulmozyme®) is the most widely used mucoactive therapy in patients with CF. It has been shown to reduce the viscoelasticity of sputum from patients with CF and enhance the clearance of secretions. Clinical trials have shown rhDNase to be a well tolerated treatment that improves pulmonary function and reduces respiratory exacerbations. However, the response to treatment is heterogeneous and only a proportion of patients with CF actually benefit from the treatment. At present, we are unable to predict which patients will benefit from rhDNase. Many CF centers have developed formal n-of-1 trials of treatment to find out who benefits and to justify prescribing the agent. rhDNase is an expensive therapy and is mainly used in patients over the age of 5 years with moderate to severe lung disease. However, studies have shown that rhDNase may be useful in patients with milder lung disease. Comparisons with another mucoactive drug, hypertonic saline, have shown rhDNase to be more effective. Recently, it has been shown that giving rhDNase on an alternate-day basis, rather than daily, is equally effective, potentially reducing costs and treatment time.

[1]  J. White,et al.  Liquefaction of viscous purulent exudates by deoxyribonuclease. , 1950, Lancet.

[2]  M. Konstan,et al.  Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. , 1994, American journal of respiratory and critical care medicine.

[3]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Genetic Analysis , 1989, Science.

[4]  D. Geddes,et al.  Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. , 1995, Respiratory medicine.

[5]  D. Geddes,et al.  Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. , 1995, The European respiratory journal.

[6]  M. King,et al.  Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. , 1997, Thorax.

[7]  D. Geddes,et al.  Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. , 1995, Thorax.

[8]  Charles A. Johnson,et al.  Effects of 12-Week Administration of Dornase Alfa in Patients with Advanced Cystic Fibrosis Lung Disease , 1996 .

[9]  R. Crystal,et al.  A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. , 1992, The New England journal of medicine.

[10]  P. Shiels,et al.  Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis. , 1996, Thorax.

[11]  J. Riedler,et al.  Hypertonic saline challenge in an epidemiologic survey of asthma in children. , 1994, American journal of respiratory and critical care medicine.

[12]  M. King,et al.  Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. , 1997, American journal of respiratory and critical care medicine.

[13]  M. Preece,et al.  Short-term effects of chest physiotherapy on pulmonary function in children with cystic fibrosis. , 1980, Respiration; international review of thoracic diseases.

[14]  P. Shah,et al.  A Case-Controlled Study with Dornase Alfa to Evaluate Impact on Disease Progression over a 4-Year Period , 2001, Respiration.

[15]  B. Bake,et al.  Impaired lung function in patients with IgA deficiency and low levels of IgG2 or IgG3. , 1985, The New England journal of medicine.

[16]  B. Ramsey,et al.  Consensus conference: Practical applications of pulmozyme® september 22, 1993 , 1994, Pediatric pulmonology.

[17]  R. Ellison,et al.  Killing of gram-negative bacteria by lactoferrin and lysozyme. , 1991, The Journal of clinical investigation.

[18]  G. Barbero,et al.  Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. , 1959, Pediatrics.

[19]  J. P. Sy,et al.  A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. , 2001, The Journal of pediatrics.

[20]  S. Fitzsimmons,et al.  The changing epidemiology of cystic fibrosis. , 1993, The Journal of pediatrics.

[21]  S. Shak,et al.  Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis , 1993, The Lancet.

[22]  R. Gibson,et al.  Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. , 1993, The American review of respiratory disease.

[23]  M. Lethem,et al.  The role of mucous glycoproteins in the rheologic properties of cystic fibrosis sputum. , 1990, The American review of respiratory disease.

[24]  M. Zach,et al.  The role of recombinant human DNase in the treatment of patients with cystic fibrosis : many promises , more problems , 2022 .

[25]  M. T. Williams.  Chest physiotherapy and cystic fibrosis. Why is the most effective form of treatment still unclear? , 1994, Chest.

[26]  G. Oster,et al.  Use of rhDNase Therapy and Costs of Respiratory-Related Care in Patients with Cystic Fibrosis , 2000, The Annals of pharmacotherapy.

[27]  S. Shak,et al.  Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Milan Macek,et al.  Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.

[29]  P. Phelan,et al.  Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis , 1995, BMJ.

[30]  R. Grieve,et al.  Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial , 2001, The Lancet.

[31]  P. Janmey,et al.  Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. , 1994, Science.

[32]  J. Morton,et al.  Short‐term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis , 1996, Pediatric pulmonology.

[33]  M. Ballmann,et al.  Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. , 2002, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[34]  A. B. Prasad,et al.  British National Formulary , 1994 .

[35]  E. Main,et al.  Finding evidence to support airway clearance techniques in cystic fibrosis. , 1998, Disability and rehabilitation.

[36]  M. King,et al.  Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. , 1996, American journal of respiratory and critical care medicine.

[37]  G. Oster,et al.  Effects of Recombinant Human DNase Therapy on Healthcare use and Costs in Patients with Cystic Fibrosis , 1995, The Annals of pharmacotherapy.

[38]  J. Pilewski,et al.  Role of CFTR in airway disease. , 1999, Physiological reviews.

[39]  L. Kuhns,et al.  Use of computerized tomography and chest X‐rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: A preliminary study * , 2001, Pediatric pulmonology.

[40]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[41]  M. Rosenthal,et al.  Retrospective review of the effects of rhDNase in children with cystic fibrosis , 1997, Pediatric pulmonology.

[42]  Melvin Berger,et al.  Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology , 1997, Pediatric pulmonology.

[43]  M. Drummond,et al.  A Multinational Economic Evaluation of rhDNase in the Treatment of Cystic Fibrosis , 1996, International Journal of Technology Assessment in Health Care.

[44]  J. Hayes,et al.  Ultrastructural localization of endogenous peroxidase in the lower respiratory tract of the guinea pig , 2004, Cell and Tissue Research.

[45]  C. Metcalfe,et al.  Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis , 2002, Thorax.

[46]  R. Auckenthaler,et al.  Aerosolized rhDNase in cystic fibrosis: effect on leucocyte proteases in sputum. , 1996, The European respiratory journal.

[47]  L. Tsui,et al.  Identification of the cystic fibrosis gene: chromosome walking and jumping. , 1989, Science.

[48]  C. Metcalfe,et al.  Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. , 2002, American journal of respiratory and critical care medicine.

[49]  S. Shak,et al.  Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. , 1992, JAMA.

[50]  D. Brooks,et al.  Chest physical therapy management of patients with cystic fibrosis. A meta-analysis. , 1995, American journal of respiratory and critical care medicine.

[51]  P. Raskin.  Bronchospasm after inhalation of pancreatic dornase. , 1968, The American review of respiratory disease.

[52]  Charles A. Johnson,et al.  Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis , 1998, Pediatric pulmonology.

[53]  R. Boucher,et al.  Human airway ion transport. Part two. , 1994, American journal of respiratory and critical care medicine.

[54]  H. Fuchs,et al.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. , 1994, The New England journal of medicine.

[55]  D. Riches,et al.  Early pulmonary inflammation in infants with cystic fibrosis. , 1995, American journal of respiratory and critical care medicine.

[56]  J. Lieberman.  Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. , 1968, JAMA.

[57]  U. Wahn,et al.  Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. , 2004, American journal of respiratory and critical care medicine.

[58]  M. Corey,et al.  Role of conventional physiotherapy in cystic fibrosis. , 1988, The Journal of pediatrics.

[59]  M. King,et al.  Respiratory mucus from asymptomatic smokers is better hydrated and more easily cleared by mucociliary action. , 1992, The American review of respiratory disease.

[60]  S. Anderson,et al.  Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects. , 1996, The European respiratory journal.

[61]  Medicine's Role in Mental Health Promotion , 1961 .

[62]  I. Ziment.  Respiratory pharmacology and therapeutics , 1978 .

[63]  A. Coates,et al.  Immediate and long-term effects of chest physiotherapy in patients with cystic fibrosis. , 1983, The Journal of pediatrics.

[64]  B. Strandvik,et al.  Dornase alfa in the treatment of cystic fibrosis in Europe: A report from the Epidemiologic Registry of Cystic Fibrosis , 2003, Pediatric pulmonology.

[65]  C. Basbaum,et al.  The serous cell. , 1990, Annual review of physiology.

[66]  E. Witebsky,et al.  Aerosolized pancreatic dornase and antibiotics in pulmonary infections: use in patients with postoperative and nonoperative infections. , 1961, JAMA.

[67]  C. Wallis,et al.  Recombinant human deoxyribonuclease for cystic fibrosis. , 2003, The Cochrane database of systematic reviews.

[68]  A. Davidson,et al.  Airway clearance techniques in the treatment of cystic fibrosis. , 1996, Current opinion in pulmonary medicine.

[69]  J. Widdicombe,et al.  Regulation of human airway surface liquid. , 1995, Respiration physiology.

[70]  A. Silberberg,et al.  The role of mucus in transport by cilia. , 1970, The American review of respiratory disease.

[71]  C. Milla.  Long term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis , 1998, Thorax.

[72]  D. Geller.  Aerosolized dornase alfa in cystic fibrosis: Is there a role in the management of patients with early obstructive lung disease? , 1997, Pediatric pulmonology.

[73]  G. Redding,et al.  Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. , 1988, The Journal of pediatrics.

[74]  S. Randell,et al.  Evidence for Periciliary Liquid Layer Depletion, Not Abnormal Ion Composition, in the Pathogenesis of Cystic Fibrosis Airways Disease , 1998, Cell.

[75]  P. Shah,et al.  The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis. , 1996, The European respiratory journal.